홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

DL-Dopa

HCID 836
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
5796-17-8
표준 SMILES
NC(Cc1ccc(O)c(O)c1)C(=O)O
InChIKey
WTDRDQBEARUVNC-UHFFFAOYSA-N
분자식
C9H11NO4
평균 분자량
197.19 g/mol
단동위원소 질량
197.06880783

개요

Dopa is a hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring. It has a role as a human metabolite. It is a hydroxyphenylalanine, a tyrosine derivative and a non-proteinogenic alpha-amino acid.

이름 및 식별자

우선 이름
DL-Dopa
IUPAC
2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
영어명
D-DOPA
분자식
C9H11NO4
분자량
197.19

이름 및 동의어

DL-DOPA63-84-32-Amino-3-(3,4-dihydroxyphenyl)propanoic aciddihydroxyphenylalanineDL-Dioxyphenylalanine3-Hydroxy-DL-tyrosineDL-3,4-Dopa(+-)-DopaDL-beta-(3,4-Dihydroxyphenyl)alanine(+-)-3-(3,4-Dihydroxyphenyl)alanineQI9C343R60NSC-16940
이름 더 보기
Levodopa Impurity D3,4-DIHYDROXY-D-PHENYLALANINE(R)-2-AMino-3-(3,4-dihydroxyphenyl)propanoic acidD-DOPADextrodopaD-DOPA USP/EP/BP3-HydroxytyrosineD-3-HYDROXYTYROSINE3-HYDROXY-D-TYROSINEH-D-TYR(3-HYDROXY)-OH
DOPA, DL-ALANINE, 3-(3,4-DIHYDROXYPHENYL)-, DL-DTXSID8020549CHEBI:491683 Hydroxy DL tyrosinebeta HydroxytyrosineRefChem:5899393,4 Dihydroxyphenylalanine

데이터베이스 식별자

CAS
5796-17-8、63-84-3
PubChem CID
836
DTXSID
DTXSID8020549
ChEMBL
CHEMBL351042
ChEBI
CHEBI:49168
UNII
QI9C343R60
EC Number
200-566-0
Nikkaji
J128.150J

물성

구조 계산 물성

XLogP
-2.7
극성 표면적
104 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
5
회전 가능 결합 수
3
무거운 원자 수
14
형식 전하
0
복잡도
209

실험 및 물리화학적 성질

Chemical ClassesBiological Agents -> Amino Acids and Derivatives
DrugsPharmaceuticals
Solubility3.6 mg/mL
Melting Point270 °C
Physical Description · 2건

Solid; [Merck Index] White solid; [Sigma-Aldrich MSDS]

Solid

Dissociation Constants2.21

물리화학적 성질

녹는점
276 · 276-278 °C(lit.)
끓는 점
448.4 · 448.4±45.0 °C(Predicted)
밀도
1.468 · 1.468±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
0.5 M · 0.5M HCl: 가용성
물리적 상태
가루
산도 계수 (pKa)
2.24 · 2.24±0.20(Predicted)
색상
흰색에서 황갈색까지
Merck
13 · 13,3454

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (16.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 48 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationChemical: DL-Tyrosine, 3-hydroxy-
Hazards SummaryA skin and strong eye irritant; [Sigma-Aldrich MSDS] See Levodopa.
Hazard Classes and CategoriesAcute Tox. 4 (16.7%)

독성 정보

Treatment · 2건

Hospitalization is advised, and general supportive measures should be employed, along with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular, by decreasing its absorption/reabsorption from the GI tract. Intravenous fluids should be administered judiciously and an adequate airway maintained. The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed. Electrocardiographic monitoring should be instituted and the patient carefully observed for the development of arrhythmias; if required, appropriate antiarrhythmic therapy should be given. The possibility that the patient may have taken other drugs, increasing the risk of drug interactions (especially catechol-structured drugs) should be taken into consideration. Hemodialysis or hemoperfusion is unlikely to reduce entacapone levels due to its high binding to plasma proteins. (L1712)

화학 및 산업

약리 정보

Metabolism/Metabolites · 2건

95% of an administered oral dose of levodopa is pre-systemically decarboxylated to dopamine by the L-aromatic amino acid decarboxylase (AAAD) enzyme in the stomach, lumen of the intestine, kidney, and liver. Levodopa also may be methoxylated by the hepatic catechol-O-methyltransferase (COMT) enzyme system to 3-O-methyldopa (3-OMD), which cannot be converted to central dopamine. Half Life: 50 to 90 minutes

Uremic toxins tend to accumulate in the blood either through dietary excess or through poor filtration by the kidneys. Most uremic toxins are metabolic waste products and are normally excreted in the urine or feces.

MeSH Pharmacological ClassificationAny drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
Cellular LocationsCytoplasm

용도 및 제조

Uses · 4건

Dopa is an amino acid in the seedlings, pods, and beans of broad beans and velvet beans; [Merck Index]

Use (kg) in Switzerland (2009): >2500

For the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication.

Naturally produced by the body (endogenous).

응용 분야

용도D-DOPA (Levodopa EP Impurity D) is a DOPA enantiomer that lacks biological activity.

추가 설명

정의ChEBI: The D-enantiomer of dopa.

관련 반응

10건
반응 기록 만들기
HRID 176932 반응식
HRID 176932반응물로
HRID 203066 반응식
HRID 203066반응물로
HRID 282565 반응식
HRID 282565반응물로
HRID 543233 반응식
HRID 543233반응물로
HRID 1032885 반응식
HRID 1032885생성물로
HRID 1153526 반응식
HRID 1153526반응물로
HRID 1202904 반응식
HRID 1202904반응물로
HRID 1205047 반응식
HRID 1205047반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
BRN
2417637 · 2417637
안정성
흡습성
InChI
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m1/s1
InChIKey
WTDRDQBEARUVNC-ZCFIWIBFSA-N
SMILES
C(O)(=O)[C@@H](CC1=CC=C(O)C(O)=C1)N

화학적 성질

Tan Solid

Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored.

Health EffectsChronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.
Exposure Routes · 2건

Levodopa is rapidly absorbed from the proximal small intestine by the large neutral amino acid (LNAA) transport carrier system.

Endogenous, Ingestion, Dermal (contact)

Toxicity Summary · 2건

Striatal dopamine levels in symptomatic Parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine.

Uremic toxins such as dihydroxyphenylalanine are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869).

Signs and Symptoms · 1건

As a uremic toxin, this compound can cause uremic syndrome. Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present.

Carcinogen Classification · 2건

No indication of carcinogenicity to humans (not listed by IARC).

No indication of carcinogenicity to humans (not listed by IARC).

Toxicity DataLD50: 2363 mg/kg (Oral, Mouse) (A308) LD50: 609 mg/kg (Oral, Rabbit) (A308) LD50: 1780 mg/kg (Oral, Rat) (A308)

안전 데이터

wgk
3
HS 번호
2922500090
F 고인화성물질
10-23
스토리지 클래스
11 - Combustible Solids